Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects

Acta Neurologica Scandinavica

Volumn 121, Issue 4, 2010, Pages 257-264

  Almeida, L ^a,b   Nunes, T ^a   Sicard, E ^c   Rocha, J F ^a   Falcao A ^d   Brunet, J S ^e   Lefebvre, M ^c   Soares Da Silva, P ^a,b  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b University of Porto   (Portugal)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^d Health Consulting   (Portugal)

^e PHARSIGHT CORPORATION   (Canada)

Author keywords

Anti epileptic drugs; Drug interactions; Eslicarbazepine acetate; Healthy subjects; Lamotrigine; Pharmacokinetics

Indexed keywords

ESLICARBAZEPINE ACETATE; LAMOTRIGINE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMAL DREAMING; ABNORMAL SENSATION; ADULT; ANXIETY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; ATTENTION; BACKACHE; BLURRED VISION; CHILL; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DIZZINESS; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; DRY LIP; DYSARTHRIA; EYE IRRITATION; FATIGUE; FLATULENCE; HEART PALPITATION; HEAVY FEELING; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; INJURY; INSOMNIA; LACRIMATION; LIMB PAIN; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MORNING DOSAGE; MOUTH PARESTHESIA; MUSCULOSKELETAL PAIN; NAUSEA; NECK PAIN; NORMAL HUMAN; OPEN STUDY; PARESTHESIA; PHOTOPSIA; PLASMA CONCENTRATION-TIME CURVE; PRURITUS; SIDE EFFECT; SOMNOLENCE; SORE THROAT; SYSTOLIC BLOOD PRESSURE; THIRST; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VOMITING; XEROSIS; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTICONVULSANTS; AREA UNDER CURVE; DIBENZAZEPINES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; HUMANS; MALE; MIDDLE AGED; TRIAZINES; YOUNG ADULT;

EID: 77749279921     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2009.01233.x     Document Type: Article

References (24)

1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000 342 : 314 319.
2. Ambrosio AF, Soares-da-silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 2002 27 : 121 130.
3. Benes J, Parada A, Figueiredo AA et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5- carboxamide derivatives. J Med Chem 1999 42 : 2582 2587.
4. Elger C, Halász P, Maia J, Almeida L, Soares-da-silva P Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009 50 : 454 463.
5. Elger C, Bialer M, Cramer JA, Maia J, Almeida L, Soares-da-silva P. Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 2007 48 : 497 504.
6. Hainzl D, Parada A, Soares-da-silva P. Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res 2001 44 : 197 206.
7. Volosov A, Xiaodong S, Perucca E, Yagen B, Sintov A, Bialer M. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 1999 66 : 547 553.
8. Almeida L, Falcão A, Maia J, Mazur D, Gellert M, Soares-da-silva P. Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol 2005 45 : 1062 1066.
9. Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol 2008 64 : 267 273.
10. Vaz-da-silva M, Nunes T, Soares E et al. Eslicarbazepine acetate pharmacokinetics after single and repated doses in healthy subjects. Epilepsia 2005 46 : 191.
11. Maia J, Vaz-da-silva M, Almeida L et al. Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R&D 2005 6 : 201 206.
12. Falcao A, Maia J, Almeida L, Mazur D, Gellert M, Soares-da-silva P. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos 2007 28 : 249 256.
13. Maia J, Almeida L, Falcão A et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther 2008 46 : 119 130.
14. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res 2007 73 : 1 52.
15. French JA, Kanner AM, Bautista J et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004 62 : 1261 1273. (Pubitemid 38526036)
16. Tomson T, Stephen LJ, Brodie MJ. Lamotrigine. In : Engel J et al, eds. Epilepsy: a comprehensive textbook. Philadelphia : Lippincott Williams & Wilkins, 2008 1575 1582.
17. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987 42 : 535 541.
18. Falcão A, Maia J, Almeida L, Mazur D, Gellert M, Soares-da-silva P. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos 2007 28 : 249 256.
19. Almeida L, Soares-da-silva P. Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol 2004 44 : 906 918.
20. Loureiro AI, Fernandes-lopes C, Bonifácio MJ, Wright LC, Soares-da-silva P. Hepatic UDP-glucuronosyltransferases responsible for eslicarbazepine glucuronidation. Proceedings of the Annual Meeting of the Portuguese Pharmacological Society 2008, Lisbon, Portugal.
21. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 2006 34 : 1055 1062.
22. Anonymous. Note for Guidance on the Investigation of Drug Interactions. Committee for Proprietary Medicinal Products, European Medicines Agency, London. CPMP/EWP/560/95. 1997.
23. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997 43 : 457 465.
24. Biton V. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol 2006 2 : 1009 1018.